Global Non-Invasive Liquid Biopsy Market

Focus on Offering, Sample, Application, Technology, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

Published Year: 2021
SKU: BHP1090SA

5250

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Product Definition

1.1    Inclusion and Exclusion

2 Market Scope

2.1    Scope of the Study
2.2    Key Questions Answered in the Report

3 Research Methodology

3.1    Global Non-Invasive Liquid Biopsy Market: Research Methodology
3.2    Data Sources
         3.2.1    Primary Data Sources
         3.2.2    Secondary Data Sources
3.3    Market Estimation Model
3.4    Criteria for Company Profiling

4 Market Overview

4.1    Market Definition
4.2    Emerging Applications of Non-Invasive Liquid Biopsy
4.3    Market Footprint and Growth Potential, $Million, 2020-2031
4.4    COVID-19 Impact on the Global Non-Invasive Liquid Biopsy Market

5 Industry Analysis

5.1    Overview
5.2    Legal Requirements and Framework in the U.S.
         5.2.1    FDA Regulation
         5.2.2    CMS Regulation
5.3    Legal Requirements and Frameworks in Europe
5.4    Legal Requirements and Frameworks in Asia-Pacific
         5.4.1    China
         5.4.2    Japan
5.5    Reimbursement Analysis
5.6    Return on Investment (RoI) Analysis

6 Market Dynamics

6.1    Overview
6.2    Impact Analysis
6.3    Market Drivers
         6.3.1    Global Increase in Cancer Prevalence
         6.3.2    Increasing Government Funding for Healthcare
         6.3.3    Rise in Patient Preference for Non-Invasive Cancer Diagnosis
         6.3.4    Growing Prominence of Precision Medicine in the Oncology Ecosystem
6.4    Market Restraints
         6.4.1    False Negatives and Positives
         6.4.2    Lack of Favorable Reimbursement Policies
         6.4.3    Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies
6.5    Market Opportunities
         6.5.1    Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy
         6.5.2    Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets

7 Competitive Landscape

7.1    Synergistic Activities
7.2    Product Approvals
7.3    Product Launches
7.4    Acquisitions
7.5    Funding and Other Activities
7.6    Market Share Analysis, 2019-2020
7.7    Growth-Share Analysis
         7.7.1    Growth-Share Analysis (by Company)
         7.7.2    Growth-Share Analysis (by Technology)
         7.7.3    Growth-Share Analysis (by Application)
7.8    Pricing Analysis
         7.8.1    Price with Sample Type

8 Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020-2031

8.1    Overview
8.2    Offering
         8.2.1    Kits
         8.2.2    Assays
8.3    Services

9 Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2021-2031

9.1    Overview
9.2    Stool
9.3    Urine
9.4    Saliva
9.5    Other Samples

10 Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031

10.1    Overview
10.2    Oncology
10.3    Reproductive Health
10.4    Metabolic Disorders
10.5    Other Applications

11 Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020-2031

11.1    Overview
11.2    Polymerase Chain Reaction (PCR)
           11.2.1    Real-Time PCR (RT-PCR)
           11.2.2    Digital PCR (dPCR)
11.3    Sequencing
           11.3.1    Next-Generation Sequencing (NGS)
           11.3.2    Sanger Sequencing
11.4    Microarray
11.5    Other Technologies

12 Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020-2031

12.1    Overview
12.2    Hospitals and Diagnostic Laboratories
12.3    Academic and Research Institutions
12.4    Other End Users

13 Global Non-Invasive Liquid Biopsy Market (by Region), $Million, 2020-2031

13.1    Overview
13.2    North America
           13.2.1    U.S.
           13.2.2    Canada
           13.2.3    North America Non-Invasive Liquid Biopsy Market (by Application)
13.3    Europe
           13.3.1    Germany
           13.3.2    U.K.
           13.3.3    France
           13.3.4    Italy
           13.3.5    Spain
           13.3.6    Netherlands
           13.3.7    Rest-of-Europe
           13.3.8    Europe Non-Invasive Liquid Biopsy Market (by Application)
13.4    Asia-Pacific (APAC)
           13.4.1    China
           13.4.2    Japan
           13.4.3    India
           13.4.4    South Korea
           13.4.5    Australia
           13.4.6    Singapore
           13.4.7    Rest-of-Asia-Pacific (RoAPAC)
           13.4.8    Asia-Pacific Non-Invasive Liquid Biopsy Market (by Application)
13.5    Latin America (LATAM)
           13.5.1    Brazil
           13.5.2    Mexico
           13.5.3    Rest-of-Latin America (RoLA)
           13.5.4    Latin America Non-Invasive Liquid Biopsy Market (by Application)
13.6    Rest-of-the-World
           13.6.1    Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application)

14 Company Profiles

14.1    Overview
14.2    Bio-Techne Corporation
           14.2.1    Company Overview
           14.2.2    Role of Bio-Techne Corporation in the Global Non-Invasive Liquid Biopsy Market
           14.2.3    Financials
           14.2.4    Key Insights About Financial Health of the Company
           14.2.5    SWOT Analysis
14.3    Endress + Hauser Group
           14.3.1    Company Overview
           14.3.2    Role of Endress + Hauser Group in the Global Non-Invasive Liquid Biopsy Market
           14.3.3    Financials
           14.3.4    Key Insights About Financial Health of the Company
           14.3.5    SWOT Analysis
14.4    Exact Sciences Corporation
           14.4.1    Company Overview
           14.4.2    Role of Exact Sciences Corporation in the Global Non-invasive Liquid Biopsy Market
           14.4.3    Financials
           14.4.4    Key Insights About Financial Health of the Company
           14.4.5    SWOT Analysis
14.5    Lonza Group AG
           14.5.1    Company Overview
           14.5.2    Role of Lonza Group AG in the Global Non-Invasive Liquid Biopsy Market
           14.5.3    Financials
           14.5.4    Key Insights About Financial Health of the Company
           14.5.5    SWOT Analysis
14.6    MDxHealth
           14.6.1    Company Overview
           14.6.2    Role of MDxHealth in the Global Non-Invasive Liquid Biopsy Market
           14.6.3    Financials
           14.6.4    Key Insights About Financial Health of the Company
           14.6.5    SWOT Analysis
14.7    Merck KGaA
           14.7.1    Company Overview
           14.7.2    Role of Merck KGaA in the Global Non-Invasive Liquid Biopsy Market
           14.7.3    Financials
           14.7.4    Key Insights About Financial Health of the Company
           14.7.5    SWOT Analysis
14.8    MutantDx
           14.8.1    Company Overview
           14.8.2    Role of MutantDx in the Global Non-Invasive Liquid Biopsy Market
           14.8.3    SWOT Analysis
14.9    Norgen Biotek Corp
           14.9.1    Company Overview
           14.9.2    Role of Norgen Biotek Corp in the Global Non-Invasive Liquid Biopsy Market
           14.9.3    SWOT Analysis
14.10    Nucleix Ltd.
             14.10.1    Company Overview
             14.10.2    Role of Nucleix Ltd. in the Global Non-Invasive Liquid Biopsy Market
             14.10.3    SWOT Analysis
14.11    Oasis Diagnostics Corporation
             14.11.1    Company Overview
             14.11.2    Role of Oasis Diagnostics Corporation in the Global Non-Invasive Liquid Biopsy Market
             14.11.3    SWOT Analysis
14.12    OraSure Technologies, Inc.
             14.12.1    Company Overview
             14.12.2    Role of OraSure Technologies, Inc. in the Global Non-Invasive Liquid Biopsy Market
             14.12.3    Financials
             14.12.4    Key Insights About Financial of the Company
             14.12.5    SWOT Analysis
14.13    PerkinElmer Inc.
             14.13.1    Company Overview
             14.13.2    Role of PerkinElmer Inc. in the Global Non-Invasive Liquid Biopsy Market
             14.13.3    Financials
             14.13.4    Key Insights About Financial Health of the Company
             14.13.5    SWOT Analysis
14.14    Predicine, Inc.
             14.14.1    Company Overview
             14.14.2    Role of Predicine, Inc. in the Global Non-Invasive Liquid Biopsy Market
             14.14.3    SWOT Analysis
14.15    QIAGEN N.V.
             14.15.1    Company Overview
             14.15.2    Role of QIAGEN N.V. in the Global Non-Invasive Liquid Biopsy Market
             14.15.3    Financials
             14.15.4    Key Insights About Financial Health of the Company
             14.15.5    SWOT Analysis
14.16    Thermo Fisher Scientific Inc.
             14.16.1    Company Overview
             14.16.2    Role of Thermo Fisher Scientific Inc. in the Global Non-Invasive Liquid Biopsy Market
             14.16.3    Financials
             14.16.4    Key Insights About Financial Health of the Company
             14.16.5    SWOT Analysis
14.17    Zymo Research Corporation
             14.17.1    Company Overview
             14.17.2    Role of Zymo Research Corporation in the Global Non-Invasive Liquid Biopsy Market
             14.17.3    SWOT Analysis

List of Tables

Table 5.1:    Classification Rules of IVDs under the IVDR
Table 5.2:    Key Coverage Providers for Non-Invasive Liquid Biopsy Tests
Table 6.1:    Likert Scale
Table 6.2:    Impact Analysis of Market Drivers
Table 6.3:    Impact Analysis of Market Restraints

List of Figures

Figure 1:    U.S. National Cancer Institute (NCI), Fiscal Budget Year-on-Year, 2013-2018
Figure 2:    Impact Analysis of Market Drivers and Market Challenges on the Global Non-Invasive Liquid Biopsy Market
Figure 3:    Global Non-Invasive Liquid Biopsy Market (by Offering), $Million,  2020 and 2031
Figure 4:    Global Non-Invasive Liquid Biopsy Market (by Sample), $Million,  2020 and 2031
Figure 5:    Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020 and 2031
Figure 6:    Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020 and 2031
Figure 7:    Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020 and 2031
Figure 8:    Global Non-invasive Liquid Biopsy Market Snapshot
Figure 2.1:    Global Non-Invasive Liquid Biopsy Market Segmentation
Figure 3.1:    Global Non-Invasive Liquid Biopsy Market: Research Methodology
Figure 3.2:    Primary Research Methodology
Figure 3.3:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Global Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 4.2:    Global Non-Invasive Liquid Biopsy Market: COVID-19 Impact Analysis
Figure 5.1:    Components Considered for Clinical Evidence as per the IVDR
Figure 5.2:    Global Non-Invasive Liquid Biopsy Market (Return on Investment (RoI) Analysis)
Figure 6.1:    Global Cancer Burden (by Region), 2018
Figure 6.2:    Increasing Government Spending for Healthcare, 2017
Figure 7.1:    Share of Key Developments and Strategies, January 2017–July 2021
Figure 7.2:    Share of Synergistic Activities (by Company), January 2017-June 2021
Figure 7.3:    Share of Product Approvals (by Company), January 2017-July 2021
Figure 7.4:    Number of Product Launches (by Company), January 2017–July 2021
Figure 7.5:    Share of Acquisitions (by Company), January 2017-July 2021
Figure 7.6:    Market Share Analysis for Global Non-Invasive Liquid Biopsy Market, $Million, 2019 and 2020
Figure 7.7:    Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market  (by Company), 2020
Figure 7.8:    Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Technology), 2020-2031
Figure 7.9:    Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Application), 2020-2031
Figure 8.1:    Global Non-Invasive Liquid Biopsy Market (by Offering)
Figure 8.2:    Global Non-Invasive Liquid Biopsy Market (by Offering), $Million,  2020 and 2031
Figure 8.3:    Global Non-Invasive Liquid Biopsy Market (by Offering), $Million,  2020-2031
Figure 8.4:    Global Non-Invasive Liquid Biopsy Market (by Offering), 2020 and 2031
Figure 8.5:    Global Non-Invasive Liquid Biopsy Market (Kits), $Million, 2020-2031
Figure 8.6:    Global Non-Invasive Liquid Biopsy Market (Assays), $Million, 2020-2031
Figure 8.7:    Global Non-Invasive Liquid Biopsy Market (Services), $Million, 2020-2031
Figure 9.1:    Global Non-Invasive Liquid Biopsy Market (by Sample), $Million,  2020-2031
Figure 9.2:    Global Non-Invasive Liquid Biopsy Market (by Sample), 2020 and 2031
Figure 9.3:    Global Non-Invasive Liquid Biopsy Market (Stool), $Million, 2020-2031
Figure 9.4:    Global Non-Invasive Liquid Biopsy Market (Urine), $Million, 2020-2031
Figure 9.5:    Global Non-Invasive Liquid Biopsy Market (Saliva), $Million, 2020-2031
Figure 9.6:    Global Non-Invasive Liquid Biopsy Market (Other Samples), $Million,  2020-2031
Figure 10.1:    Global Non-Invasive Liquid Biopsy Market (by Application)
Figure 10.2:    Global Non-Invasive Liquid Biopsy Market (by Application), $Million,  2020-2031
Figure 10.3:    Global Non-Invasive Liquid Biopsy Market (Oncology), $Million,  2020-2031
Figure 10.4:    Global Non-Invasive Liquid Biopsy Market (Reproductive Health), $Million, 2020-2031
Figure 10.5:    Global Non-Invasive Liquid Biopsy Market (Metabolic Disorders), $Million, 2020-2031
Figure 10.6:    Global Non-Invasive Liquid Biopsy Market (Other Applications), $Million, 2020-2031
Figure 11.1:    Global Non-Invasive Liquid Biopsy Market (by Technology)
Figure 11.2:    Global Non-Invasive Liquid Biopsy Market (by Technology), 2020 and 2031
Figure 11.3:    Global Non-Invasive Liquid Biopsy Market (PCR), $Million, 2020-2031
Figure 11.4:    Global Non-Invasive Liquid Biopsy Market (PCR), 2020 and 2031
Figure 11.5:    Global Non-Invasive Liquid Biopsy Market (RT-PCR, by PCR), $Million, 2020-2031
Figure 11.6:    Global Non-Invasive Liquid Biopsy Market (dPCR, by PCR), $Million, 2020-2031
Figure 11.7:    Global Non-Invasive Liquid Biopsy Market (Sequencing), $Million,  2020-2031
Figure 11.8:    Global Non-Invasive Liquid Biopsy Market (Sequencing), 2020 and 2031
Figure 11.9:    Global Non-Invasive Liquid Biopsy Market (NGS, by Sequencing), $Million, 2020-2031
Figure 11.10:    Global Non-Invasive Liquid Biopsy Market (Sanger Sequencing, by Sequencing), $Million, 2020-2031
Figure 11.11:    Global Non-Invasive Liquid Biopsy Market (Microarray), $Million,  2020-2031
Figure 11.12:    Global Non-Invasive Liquid Biopsy Market (Other Technologies), $Million, 2020-2031
Figure 12.1:    Global Non-Invasive Liquid Biopsy Market (by End User)
Figure 12.2:    Global Non-Invasive Liquid Biopsy Market (by End User), $Million,  2020-2031
Figure 12.3:    Global Non-Invasive Liquid Biopsy Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2031
Figure 12.4:    Global Non-Invasive Liquid Biopsy Market (Academic and Research Institutions), $Million, 2020-2031
Figure 12.5:    Global Non-Invasive Liquid Biopsy Market (Other End Users), $Million,  2020-2031
Figure 13.1:    Global Non-Invasive Liquid Biopsy Market (by Region): Market Snapshot
Figure 13.2:    Global Non-Invasive Liquid Biopsy Market (by Region), $Million,  2020-2031
Figure 13.3:    North America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.4:    North America: Market Dynamics
Figure 13.5:    North America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
Figure 13.6:    U.S. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.7:    Canada Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.8:    North America Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 13.9:    Europe Non-invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.10:    Europe: Market Dynamics
Figure 13.11:    Europe Non-Invasive Liquid Biopsy Market (by Country), $Million,  2020-2031
Figure 13.12:    Germany Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.13:    U.K. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.14:    France Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.15:    Italy Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.16:    Spain Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.17:    Netherlands Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.18:    Rest-of-Europe Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.19:    Europe Non-Invasive Liquid Biopsy Market (by Application), $Million,  2020-2031
Figure 13.20:    Asia-Pacific Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.21:    APAC Non-Invasive Liquid Biopsy Market (by Country), $Million,  2020-2031
Figure 13.22:    China Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.23:    Japan Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.24:    India Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.25:    South Korea Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.26:    Australia Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.27:    Singapore Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.28:    RoAPAC Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.29:    APAC Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 13.30:    Latin America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.31:    Latin America: Market Dynamics
Figure 13.32:    Latin America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
Figure 13.33:    Brazil Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.34:    Mexico Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.35:    RoLA Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.36:    LATAM Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 13.37:    Rest-of-the-World Non-Invasive Liquid Biopsy Market, $Million,  2020-2031
Figure 13.38:    Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 14.1:    Total Number of Companies Profiled
Figure 14.2:    Bio-Techne Corporation: Service Portfolio
Figure 14.3:    Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 14.4:    Bio-Techne Corporation: Revenue (by Segment), 2018-2020
Figure 14.5:    Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 14.6:    Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 14.7:    Bio-Techne Corporation: SWOT Analysis
Figure 14.8:    Endress + Hauser Group: Product Portfolio
Figure 14.9:    Endress + Hauser Group: Overall Financials, 2018-2020
Figure 14.10:    Endress + Hauser Group: Revenue (by Segment), 2018-2020
Figure 14.11:    Endress + Hauser Group: Revenue (by Region), 2018-2020
Figure 14.12:    Endress + Hauser Group: R&D Expenditure, 2018-2020
Figure 14.13:    Endress + Hauser Group: SWOT Analysis
Figure 14.14:    Exact Sciences Corporation: Service Portfolio
Figure 14.15:    Exact Sciences Corporation: Overall Financials, 2018-2020
Figure 14.16:    Exact Sciences Corporation: Revenue (by Segment), 2018-2020
Figure 14.17:    Exact Sciences Corporation: Revenue (by Region), 2018-2020
Figure 14.18:    Exact Sciences Corporation: R&D Expenditure, 2018-2020
Figure 14.19:    Exact Sciences Corporation: SWOT Analysis
Figure 14.20:    Lonza Group AG: Product Portfolio
Figure 14.21:    Lonza Group AG: Overall Financials, 2018-2020
Figure 14.22:    Lonza Group AG: Revenue (by Segment), 2018-2020
Figure 14.23:    Lonza Group AG: Revenue (by Region), 2018-2020
Figure 14.24:    Lonza Group AG: R&D Expenditure, 2018-2020
Figure 14.25:    Lonza Group AG: SWOT Analysis
Figure 14.26:    MDxHealth: Service Portfolio
Figure 14.27:    MDxHealth: Overall Financials, 2018-2020
Figure 14.28:    MDxHealth: Revenue (by Segment), 2018-2020
Figure 14.29:    MDxHealth: Revenue (by Region), 2018-2020
Figure 14.30:    MDxHealth: R&D Expenditure, 2018-2020
Figure 14.31:    MDxHealth: SWOT Analysis
Figure 14.32:    Merck KGaA: Product Portfolio
Figure 14.33:    Merck KGaA: Overall Financials, 2018-2020
Figure 14.34:    Merck KGaA: Revenue (by Segment), 2018-2020
Figure 14.35:    Merck KGaA: Revenue (by Region), 2018-2020
Figure 14.36:    Merck KgaA: R&D Expenditure, 2018-2020
Figure 14.37:    Merck KGaA: SWOT Analysis
Figure 14.38:    MutantDx: Product Portfolio
Figure 14.39:    MutantDx: SWOT Analysis
Figure 14.40:    Norgen Biotek Corp: Product Portfolio
Figure 14.41:    Norgen Biotek Corp: SWOT Analysis
Figure 14.42:    Nucleix Ltd.: Product Portfolio
Figure 14.43:    Nucleix Ltd.: SWOT Analysis
Figure 14.44:    Oasis Diagnostics Corporation: Product Portfolio
Figure 14.45:    Oasis Diagnostics Corporation: SWOT Analysis
Figure 14.46:    OraSure Technologies, Inc.: Product Portfolio
Figure 14.47:    OraSure Technologies, Inc.: Overall Financials, 2018-2020
Figure 14.48:    OraSure Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 14.49:    OraSure Technologies, Inc.: Revenue (by Molecular Solutions),  2019-2020
Figure 14.50:    OraSure Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 14.51:    OraSure Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 14.52:    OraSure Technologies, Inc.: SWOT Analysis
Figure 14.53:    PerkinElmer Inc.: Product Portfolio
Figure 14.54:    PerkinElmer Inc.: Overall Financials, 2018-2020
Figure 14.55:    PerkinElmer Inc.: Revenue (by Segment), 2018-2020
Figure 14.56:    PerkinElmer Inc.: Revenue (by Region), 2018-2020
Figure 14.57:    PerkinElmer Inc.: R&D Expenditure, 2018-2020
Figure 14.58:    PerkinElmer Inc.: SWOT Analysis
Figure 14.59:    Predicine, Inc.: Service Portfolio
Figure 14.60:    Predicine, Inc.: SWOT Analysis
Figure 14.61:    QIAGEN N.V.: Product Portfolio
Figure 14.62:    QIAGEN N.V.: Overall Financials, 2018-2020
Figure 14.63:    QIAGEN N.V.: Revenue (by Segment), 2018-2020
Figure 14.64:    QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 14.65:    QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 14.66:    QIAGEN N.V.: SWOT Analysis
Figure 14.67:    Thermo Fisher Scientific Inc.: Product Portfolio
Figure 14.68:    Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 14.69:    Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 14.70:    Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 14.71:    Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 14.72:    Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 14.73:    Zymo Research Corporation: Product Portfolio
Figure 14.74:    Zymo Research Corporation: SWOT Analysis

FAQ's

What is the estimated growth rate global non-invasive liquid biopsy market in the coming years?

The global non-invasive liquid biopsy market was estimated at $1.48 Billion in 2021 and is expected to grow at a CAGR of 20.38% during the forecast period.

What are the possible opportunities that can boost the growth of the global non-invasive liquid biopsy market?

Opportunities that can boost the growth of the market amalgamation of artificial intelligence (AI) with non-invasive liquid biopsy and massive scope for the adoption of non-invasive liquid biopsy tests in the emerging markets.

What are factors driving the growth of global non-invasive liquid biopsy market?

Factors driving the growth of the market, include global increase in cancer prevalence and increasing government funding for healthcare.

What are the applications for which non-invasive liquid biopsy can be used?

Applications for which non-invasive liquid biopsy can be used include oncology, reproductive health, metabolic disorders, and other applications.

Which are the top market players operating in the global non-invasive liquid biopsy market?

Bio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Zymo Research Corporation

You may also like

Published Year: 2020

Global Liquid Biopsy Market: Focus on Market Segmentation by Product Type, by Indication Type, by Te

The global liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6...

 
Published Year: 2020

Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Br

The minimally invasive biopsy technologies market industry analysis by BIS Research projects...

 

Global Non-Invasive Liquid Biopsy Market

Focus on Offering, Sample, Application, Technology, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031